Open Access Articles- Top Results for Bambuterol


Systematic (IUPAC) name
(RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
Clinical data
AHFS/ International Drug Names
  • Unknown
  • (Prescription only)
Pharmacokinetic data
Bioavailability 20%
Metabolism Hepatic, extensive
Further metabolized to terbutaline by plasma cholinesterase
Half-life 13 hours (bambuterol)
21 hours (terbutaline)
Excretion Renal
81732-46-9 7pxY
PubChem CID 54766
DrugBank DB01408 7pxN
ChemSpider 49466 7pxY
UNII Y1850G1OVC 7pxN
KEGG D07377 7pxY
ChEBI CHEBI:553827 7pxN
ChEMBL CHEMBL521589 7pxY
Chemical data
Formula C18H29N3O5
367.44 g/mol
 14pxN (what is this?)  (verify)

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol (INN).[1]


As other LABAs, bambuterol is used in the long-term management of persistent asthma.[1] It should not be used as a rescue medication for short-term relief of asthma symptoms.


Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment, but dose adjustments are necessary.[1]

Adverse effects

The adverse effect profile of bambuterol is similar to that of salbutamol, and may include fatigue, nausea, palpitations, headache, dizziness and tremor.[1]


Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).[2]

Bambuterol acts as a cholinesterase inhibitor, and can prolong the duration of action of suxamethonium (succinylcholine) and other drugs whose breakdown in the body depends on cholinesterase function.[1] Butyrylcholinesterase activity returns to normal approximately two weeks after bambuterol is stopped.[3] It can also enhance the effects of non-depolarizing neuromuscular blockers, such as vecuronium bromide.[2]


  1. ^ a b c d e Sweetman, Sean C., ed. (2009). "Bronchodilators and Anti-asthma Drugs". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1115–16. ISBN 978-0-85369-840-1. 
  2. ^ a b Sweetman (2009), pp. 1132–33.
  3. ^ Sitar DS (October 1996). "Clinical pharmacokinetics of bambuterol". Clin Pharmacokinet 31 (4): 246–56. PMID 8896942. doi:10.2165/00003088-199631040-00002.